ワクチン・アジュバント研究センター
Center for Vaccine and Adjuvant Research(CVAR) Kick-Off Meeting

キックオフ ミーティング
同時開催：2nd Asia Vaccine and Immunotherapeutic Workshop

2017 年 10 月 20 日（金）/ October 20, 2017
千里ライフサイエンスセンター / Senri Life Science Center, Osaka, Japan＜主 催 / Organizer＞

国立研究開発法人医薬基盤・健康・栄養研究所 ワクチン・アジュバント研究センター

Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)＜協 賛 / Supporting organization＞

国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development (AMED)Contents
Introducing

CVAR//CVAR のご紹介･目次････････････････････････････P~PProgram/ プログラ

ム･･････････････････････････････････････････････････P ~ P

Abstracts for oral presentation / 講演要旨･･････････････････････････O~O
Abstracts for poster presentation / ポスター発表要旨･･････････････P ~PVenue / 会場

Life Hall

Reception
受付

Science HallVenue◆Oral presentation
13:00-14:40
15:20-17:00◆Poster presentation

14:40-15:20

Notice / 注意
（１） Smoking is allowed only in the designated room on the 6th floor.
喫煙される方は、６階の喫煙場所でお願いします。館内のそれ以外の場所での喫煙は禁じられています。
（２）

Please turned off your cell phone or put them on vibrate during the presentations.
講演中は、携帯電話は電源を切るかマナーモードにしてください。

Program for oral presentation/

講演プログラムRegistration （12:30）■

1. Opening remarks （13:00）
Yoshihiro Yoneda, MD, Ph.D.
/ Director General of National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)
2. 2nd Asia Vaccine and Immunotherapeutic Workshop ～ Special lectures for Asian Vaccine R&D（13：05~14:40）＜session chair＞ Ken J. Ishii / NIBIOHN【O-01】13:05~13:10「Introduction and future perspective of ISV」
Margaret Ann Liu, MD / President, International Society for Vaccines（ProTherImmune / Karolinska Institutet / University of California, San Francisco)【O-02】13:10~13:40「Clinical development of SE36 malaria vaccine」
Toshihiro Horii, Ph.D. / Department of Molecular Protozoology, Research Institute for Microbial
Diseases (RIMD), Osaka University【O-03】13:40~14:10｢Manipulating Adjuvants to achieve augmented or suppressive immune responses」
Bin Wang, Ph.D. / Key Lab for Medical Molecular Viralogy of MOE & MOH, Shanghai Medical College,Fudan University and National Engineering Lab for Therapeutic Vaccines, China【O-04】14:10~14:40「Flagellin as a versatile adjuvant for vaccines against intractable diseases」

Joon Haeng Rhee, MD, Ph.D. / Clinical Vaccine R&D Center and Department of Microbiology,
Chonnam National University Medical School, Gwangju, Republic of Korea
３．

Poster session ＆Coffee break （14:40~15:20）◆Please feel free to come to Science Hall. Poster presenters will stand by their poster and be
prepared to answer questions from attendees.
◆Please help yourself to some coffee at the lobby.

４. Center for Vaccine and Adjuvant Research (CVAR) Kick-Off meeting （15:20~17:00）＜session chair＞ Ken J. Ishii / NIBIOHN◆Opening remarks （15:20~15:30）
Kazunari Asanuma,MD / Director of Health Sciences Division, Ministry of Health, Labour and Welfare【O-05】15:30~15:50｢Nucleic acids as an vaccine adjuvant and potential immunotherapeutics」
Ken J. Ishii, MD, Ph.D./ Center for Vaccine and Adjuvant Research (CVAR), NIBIOHN【O-06】 15:50~16:10「Diets and commensal bacteria act as natural adjuvants for the control of intestinal immune responses
against oral vaccines」
Jun Kunisawa, Ph.D. / Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN【O-07】16:10~16:30「Recombinant BCG expressing SOCS1 antagonist as a novel BCG vaccine」
Yasuhiro Yasutomi, DVM, Ph.D. / Laboratory of Translational Immunology and Tsukuba Primate
Research Center, NIBIOHN【O-08】16:30~16:50「Dynamic changes in host histone modifications and chromatin architectures to influenza virus infection」
Yumiko Imai, MD, Ph.D. / Laboratory of Regulation of Intractable Infectious Diseases, NIBIOHN
6. Closing remarks （16:50）
Koichi Yamanishi, MD, Ph.D. / Director General of the research foundation for microbial disease ofOsaka University

Program for poster presentation / ポスター発表プログラム【 October 20, 2017 （14:40 ～ 15:20）】■

Poster session : Poster presenters will stand by their poster and be prepared to answer
questions from attendees from 14:40 to 15:20.

【P-01】
Title:Immunological mechanism of Ag85B-hPIV2-based anti-tuberculosis vaccine（Ag85B-hPIV2 結核ワクチンの免疫誘導のメカニズム)
First author : 長竹

貴広 / Takahiro Nagatake

Affiliation : Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN)【P-02】
Title:Development of a divalent food poisoning vaccine using C-terminal fragment of Clostridium
perfringens enterotoxin and cholera toxin B subunit（ウエルシュ菌エンテロトキシン C 末断片とコレラトキシン B サブユニットを用いた食中毒多価ワクチンの開発)
First author : 鈴木英彦 / SUZUKI HidehikoAffiliation : Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN【P-03】
Title:Prime-boost Vaccination with CpG ODN and curdlan strongly induces both systemic and mucosal immunity（CpG ODN とカードランを用いたプライム‐ブーストワクチン法は全身免疫と粘膜免疫の両方を強く誘導する)First author : 武村直紀 / Naoki Takemura

Affiliation :1 Department of Mucosal Immunology, Graduate School of Medicine, Chiba University,
2 Division of Innate Immune Regulation, International Research and Development Center for

Mucosal Vaccines, Institute of Medical Science, The University of Tokyo【P-04】
Title:Development of bivalent subunit fusion vaccine for the prevention of toxin-mediated pathogenesisof Clostridium perfringens and enterohemorrhagic Escherichia coIi
（ウエルシュ菌エンテロトキシンと腸管出血性大腸菌 2 型ベロ毒素を標的とした 2 価サブユニット融合ワクチンの開発）

First author : 細見

晃司 / Koji Hosomi

Affiliation : Laboratory of Vaccine Materials and Gut Environmental System, NIBIOHN

【P-05】
Title:Development of Th2-Biasing CD1d Ligands Containing Modified Lipid Moieties（脂質部位の構造展開を基盤とする Th2 サイトカイン選択的 CD1d リガンドの創製研究）
First author : 井貫 晋輔 / Shinsuke Inuki
Affiliation : 1 Faculty of Science and Technology, Keio University,
2Graduate School of Pharmaceutical Sciences, Kyoto University【P-06】
Title:Development of mycobacterial glycolipids-based adjuvants using nano particle technology（ナノ粒子技術による結核菌糖脂質アジュバントの開発)
First author : 渡邊 美幸 / Miyuki Watanabe
Affiliation :Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University【P-07】
Title:Roles of SOCS1 for establishment of mycobacterial infection（マイコバクテリア感染の確立における SOCS1 の役割）
First author : 相馬 祥吾 / SOMA Shogo
Affiliation : 1 Tsukuba Primate Research Center, NIBIOHN､2Mie University Graduate School of Medicine【P-08】
Title:Innovative nanoparticle vaccine encapsulating nucleic acids against emerging infectious diseases
First author :Nao Jonai
Affiliation :Vaccine Research Laboratories, Kitasato Daiichi Sankyo Vaccine Co., LTD.
【P-09】
Title:Combination of CpG ODN and STING ligand functions as Th1-inducing adjuvant
First author : Etsushi Kuroda
Affiliation : 1Laboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research(CVAR),NIBIOHN
Laboratory of Vaccine Science, WPI Immunology Frontier Research Center, Osaka University2【P-10】
Title:A systems analysis of whole organ adjuvant transcriptomes for biomarker and target discovery
First author : Lokesh P. TRIPATHI
Affiliation :Laboratory of Bioinformatics , NIBIOHN【P-11】
Title:Establishment of a novel safety profiling system for vaccines and adjuvants using the genes
expression profile and statistical model（マーカー遺伝子を用いた探索的な in vivo アジュバント生物活性・安全性プロファイリング法の構築)
First author : Eita Sasaki
Affiliation :Department of Safety Research on Blood and Biological Products, National Institute ofInfectious Disease【P-12】
Title:Construction of a Transcriptome-based Toxicity and Efficacy Prediction Model of Adjuvants（トランスクリプトームに基づいたアジュバントの安全性および有効性の評価法の構築）
First author : Natsuko Kishishita
Affiliation : 1Laboratory of Mockup Vaccine, NIBIOHN､2Laboratory of Adjuvant Innovation, NIBIOHN､
3

Laboratory of Vaccine Science, Immunology Frontier Research Center, World PremierInternational Research Center, Osaka University【P-13】
Title:Assessment of K3-SPG, nano-particulate CpG DNA, as an immunotherapeutic agent in non-human primate models in vivo
（非ヒト霊長類による in vivo でのナノ微粒子化 CpG DNA である K3-SPG の免疫治療剤としての評価）
First author : 升田 雄士 / Yuji Masuta
Affiliation :1Laboratory of Adjuvant Innovation, NIBIOHN
2Laboratory of Vaccine Science, Immunology Frontier Research Center, World PremierInternational Research Center, Osaka University＜Poster Layout（Science Hall）＞

ワクチン・アジュバント研究センターキックオフミーティング プログラム・講演要旨集
Center for Vaccine and Adjuvant Research (CVAR) Kick-Off meeting Program and Abstracts(October 20, 2017, Senri Life Science Center, Osaka,Japan)
Copyright Ⓒ 2017 All rights reserved（不許複製・禁無断転載） 出版：2017 年 10 月 20
日発行：国立研究法人医薬基盤・健康・栄養研究所内 CVAR キックオフミーティング事務局